A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity

AIMS: Prasugrel is a novel thienopyridine P2Y(12) adenosine diphosphate (ADP) receptor antagonist that inhibits ADP-mediated platelet activation and aggregation. Accordingly, it may be useful in reducing platelet-related ischaemia in sickle cell disease (SCD). Exposure to prasugrel's active met...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jakubowski, Joseph A, Zhou, Chunmei, Small, David S, Winters, Kenneth J, Lachno, D Richard, Frelinger, Andrew L, Howard, Jo, Mant, Timothy G, Jurcevic, Stipo, Payne, Christopher D
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 2013
Matèries:
Clinical Trials
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3690102/
https://ncbi.nlm.nih.gov/pubmed/23171128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12042
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars